On March 17, 2021, Riva Health, a new mobile cardiology app, announced $15.5 million in funding led by Menlo Ventures. UCHealth and University of Colorado Innovation Fund also participated in the round, as well as leading Chicago healthcare investors Brandon Cruz of GoHealth and Larry Gies of Madison Industries. This investment follows on the heels of a previous round led last year by Menlo Ventures, alongside True Ventures. Riva is led by CEO Dag Kittlaus, former co-founder of both Siri and Viv, and Tuhin Sinha, Ph.D. and co-founder of one of the largest cardiovascular research studies in the world, Health eHeart. Wilson Sonsini represented Riva Health in the transaction.

Riva’s measurement technology provides novel cardiovascular data and real-time management that can be directly tied to health goals and outcomes. The application uses fingertip photoplethysmography (PPG) to measure an individual’s blood-pulse waveform (BPW), a signal that shows changes in blood flow volume and intensity. The high-resolution measurement is captured when an individual’s index finger is placed on the camera lens on the back of a phone. This novel technology is coupled with healthcare interventions provided by Riva’s own licensed healthcare providers. The comprehensive hypertension solution can be used for more rapid and high-fidelity remote patient management and to make premium heart healthcare more equitable and accessible. Riva will launch the beta of its flagship app in the summer of 2021.

The Wilson Sonsini team that advised Riva Health on the transaction includes Elton Satusky, Theo Haboucha, and Eric Hsu.

For more information, please see Riva Health's press release, or further coverage at TechCrunch and MobiHealthNews.